Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Study flow diagram.
Figuras y tablas -
Figure 1

Study flow diagram.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias summary: review authors' judgements about each risk of bias item for each included study
Figuras y tablas -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
Figuras y tablas -
Figure 3

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Oral antibiotic versus parenteral antibiotic (AB), Outcome 1 Remission at the end of treatment.
Figuras y tablas -
Analysis 1.1

Comparison 1 Oral antibiotic versus parenteral antibiotic (AB), Outcome 1 Remission at the end of treatment.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Oral antibiotic versus parenteral antibiotic (AB), Outcome 2 Remission at least 12 months after the end of treatment.
Figuras y tablas -
Analysis 1.2

Comparison 1 Oral antibiotic versus parenteral antibiotic (AB), Outcome 2 Remission at least 12 months after the end of treatment.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Oral antibiotic versus parenteral antibiotic (AB), Outcome 3 Mild adverse events.
Figuras y tablas -
Analysis 1.3

Comparison 1 Oral antibiotic versus parenteral antibiotic (AB), Outcome 3 Mild adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Oral antibiotic versus parenteral antibiotic (AB), Outcome 4 Moderate or severe adverse events.
Figuras y tablas -
Analysis 1.4

Comparison 1 Oral antibiotic versus parenteral antibiotic (AB), Outcome 4 Moderate or severe adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Oral antibiotic versus parenteral antibiotic (AB), Outcome 5 Superinfection.
Figuras y tablas -
Analysis 1.5

Comparison 1 Oral antibiotic versus parenteral antibiotic (AB), Outcome 5 Superinfection.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Oral antibiotic versus parenteral plus oral antibiotic, Outcome 1 Remission at least 12 months after the end of the treatment.
Figuras y tablas -
Analysis 2.1

Comparison 2 Oral antibiotic versus parenteral plus oral antibiotic, Outcome 1 Remission at least 12 months after the end of the treatment.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Oral antibiotic versus parenteral plus oral antibiotic, Outcome 2 Adverse events.
Figuras y tablas -
Analysis 2.2

Comparison 2 Oral antibiotic versus parenteral plus oral antibiotic, Outcome 2 Adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Parenteral plus oral antibiotics versus parenteral antibiotic, Outcome 1 Remission at least 12 months after the end of treatment.
Figuras y tablas -
Analysis 3.1

Comparison 3 Parenteral plus oral antibiotics versus parenteral antibiotic, Outcome 1 Remission at least 12 months after the end of treatment.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Parenteral plus oral antibiotics versus parenteral antibiotic, Outcome 2 Adverse events.
Figuras y tablas -
Analysis 3.2

Comparison 3 Parenteral plus oral antibiotics versus parenteral antibiotic, Outcome 2 Adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Parenteral antibiotic 1 (ceftazidime) versus parenteral antibiotic 2 (ticarcillin plus tobramycin), Outcome 1 Remission at least 12 months after the end of the treatment.
Figuras y tablas -
Analysis 4.1

Comparison 4 Parenteral antibiotic 1 (ceftazidime) versus parenteral antibiotic 2 (ticarcillin plus tobramycin), Outcome 1 Remission at least 12 months after the end of the treatment.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Parenteral antibiotic 1 (ceftazidime) versus parenteral antibiotic 2 (ticarcillin plus tobramycin), Outcome 2 Adverse events.
Figuras y tablas -
Analysis 4.2

Comparison 4 Parenteral antibiotic 1 (ceftazidime) versus parenteral antibiotic 2 (ticarcillin plus tobramycin), Outcome 2 Adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Parenteral antibiotic 1 (ceftazidime) versus parenteral antibiotic 2 (ticarcillin plus tobramycin), Outcome 3 Superinfection.
Figuras y tablas -
Analysis 4.3

Comparison 4 Parenteral antibiotic 1 (ceftazidime) versus parenteral antibiotic 2 (ticarcillin plus tobramycin), Outcome 3 Superinfection.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Oral antibiotic 1 (ciprofloxacin) versus oral antibiotic 2 (lomefloxacin), Outcome 1 Remission at least 12 months after the end of treatment.
Figuras y tablas -
Analysis 5.1

Comparison 5 Oral antibiotic 1 (ciprofloxacin) versus oral antibiotic 2 (lomefloxacin), Outcome 1 Remission at least 12 months after the end of treatment.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Oral antibiotic 1 (ciprofloxacin) versus oral antibiotic 2 (lomefloxacin), Outcome 2 Adverse events.
Figuras y tablas -
Analysis 5.2

Comparison 5 Oral antibiotic 1 (ciprofloxacin) versus oral antibiotic 2 (lomefloxacin), Outcome 2 Adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Comparison 1. Oral antibiotic versus parenteral antibiotic (AB)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Remission at the end of treatment Show forest plot

4

150

Risk Ratio (M‐H, Fixed, 95% CI)

1.04 [0.92, 1.18]

2 Remission at least 12 months after the end of treatment Show forest plot

3

118

Risk Ratio (M‐H, Fixed, 95% CI)

0.94 [0.78, 1.13]

3 Mild adverse events Show forest plot

3

118

Risk Ratio (M‐H, Fixed, 95% CI)

1.08 [0.49, 2.42]

4 Moderate or severe adverse events Show forest plot

3

91

Risk Ratio (M‐H, Fixed, 95% CI)

0.69 [0.19, 2.57]

5 Superinfection Show forest plot

3

124

Risk Ratio (M‐H, Fixed, 95% CI)

1.08 [0.33, 3.60]
Figuras y tablas -
Comparison 1. Oral antibiotic versus parenteral antibiotic (AB)
Ir a la tabla de la revisión
Comparison 2. Oral antibiotic versus parenteral plus oral antibiotic

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Remission at least 12 months after the end of the treatment Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

2 Adverse events Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected
Figuras y tablas -
Comparison 2. Oral antibiotic versus parenteral plus oral antibiotic
Ir a la tabla de la revisión
Comparison 3. Parenteral plus oral antibiotics versus parenteral antibiotic

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Remission at least 12 months after the end of treatment Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

2 Adverse events Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected
Figuras y tablas -
Comparison 3. Parenteral plus oral antibiotics versus parenteral antibiotic
Ir a la tabla de la revisión
Comparison 4. Parenteral antibiotic 1 (ceftazidime) versus parenteral antibiotic 2 (ticarcillin plus tobramycin)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Remission at least 12 months after the end of the treatment Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

2 Adverse events Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

3 Superinfection Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected
Figuras y tablas -
Comparison 4. Parenteral antibiotic 1 (ceftazidime) versus parenteral antibiotic 2 (ticarcillin plus tobramycin)
Ir a la tabla de la revisión
Comparison 5. Oral antibiotic 1 (ciprofloxacin) versus oral antibiotic 2 (lomefloxacin)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Remission at least 12 months after the end of treatment Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

2 Adverse events Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected
Figuras y tablas -
Comparison 5. Oral antibiotic 1 (ciprofloxacin) versus oral antibiotic 2 (lomefloxacin)
Ir a la tabla de la revisión